Chronic Kidney Disease

The phase 2 study will evaluate the efficacy and safety of 2 different doses of MK-2060 in patients with ESRD receiving hemodialysis via an arteriovenous graft.

Uric Acid Cleanse helps to managing uric acid levels for kidney support.

A new study warns that fluoroquinolone could increase the risk of altered mental status and hospitalizations for advanced chronic kidney disease patients, though it is rare.

Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.

American Diabetes Association updates recommendations regarding SGLT-2 inhibitors, GLP-1 RA, and finerenone for cardiovascular and renal comorbidities.

Compared to atorvastatin, rosuvastatin was associated with higher risks of blood in the urine and kidney failure that requires replacement therapy.

Belimumab (Benlysta) the first FDA-approved therapy for pediatric lupus nephritis.

Methotrexate is an immunosuppressive agent used to treat cancer, dermatology-, and rheumatology-related issues.

Expanded glomerular filtration rate (GFR) testing in the United States could be one step toward minimizing disparities in renal formulas, Beumer said.

Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .

The ability to measure GFR would be a significant advancement for clinicians in the United States.

Renvela is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Approved by the FDA in 2021, finerenone is the only non-steroidal mineralocorticoid receptor antagonist that reduces the risk of renal disease progression and cardiovascular events in adults with type 2 diabetes mellitus-mediated chronic kidney disease.

The use of certain drugs, such as statins, may lead to rhabdomyolysis.

The application is based on positive results from the ASCEND phase 3 clinical trial, assessing the efficacy and safety of daprodustat for the treatment of anemia from chronic kidney disease.

Recent studies demonstrated that renal failure, proteinuria, and histologic renal lesions can be prevented by mineralocorticoid receptor antagonists.

Despite their lower antibody responses, patients who are vaccinated receive protection from SARS-CoV-2 infection and severe disease.

Trial of empagliflozin (Jardiance) in adults with chronic kidney disease will end early based on a recommendation from the trial’s Independent Data Monitoring Committee based on clear positive efficacy.

The FDA has approved Difelikefalin injection (Korsuva; Cara Therapeutics and Vifor Pharma) for the treatment of moderate-to-severe chronic kidney disease–associated pruritus in adults undergoing hemodialysis.

Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.

Women had lower health-related quality of life at the beginning of the study, although men experienced a more rapid decline over time.

Severe or prolonged inflammation associated with glomerulonephritis can damage the kidneys.

New research raises concerns about the commonly prescribed medications used to treat heart failure and high blood pressure, though investigators say patients should continue to take them.

A survey was administered electronically to key kidney care stakeholders in 182 International Society of Nephrology (ISN)-affiliated countries, with 88% responding and 97% answering the survey items related to kidney nutrition care.

Symptoms of Gaucher disease include abdominal complaints, skeletal abnormalities, and blood disorders.